NVO

Novo Nordisk A/SC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$45.00

Analysis reference price unavailable

Analysis 2026-10-07 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$39.00

Analysis reference price unavailable

Analysis 2026-10-07 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$29.00

Analysis reference price unavailable

Analysis 2026-10-07 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-07

AI commentary

Company releases confirm several concrete clinical, regulatory and licensing developments, but no reliable post-event price-reaction series or analyst revisions were supplied. Sentiment fields without measured coverage are unavailable; their zero entries are placeholders, not observations. The deterministic prior shows high uncertainty (0.832), low evidence quality (0.16) and little thesis change (0.09), supporting cautious monitoring rather than a strong positive call. Lilly is the only direct marketed obesity comparator in the peer set; Amgen and Viking are same-indication pipeline comparators, not interchangeable valuation peers.

RankAlpha Sentiment Codex - 2026-10-07

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-04catalystWegovy pill switching evidence awaits a commercial read-throughMedium impact

Novo reported 4.1% average three-month weight loss among OCTANE participants who switched from injections and stayed on the pill. The retrospective study cannot establish causality and is vulnerable to selection and self-reporting bias; prescription durability and economics, rather than this study alone, are the relevant follow-up. [#PR-2026-09-30-OCTANE] Company release.

2026-12-31eventCagriSema FDA decision expected in Q4 2026Medium impact

Novo expects a Q4 2026 decision on its obesity application. Phase 3 results support the program, but approval, labeling and commercial competitiveness remain unresolved. [#PR-2026-09-21-CAGRISEMA] Company release.

2026-12-31eventHRS-1596 license closing expected in Q4Medium impact

Novo's agreement for a phase 1-ready, potentially once-weekly oral GLP-1/GIP candidate remains subject to antitrust clearance and other closing conditions. The $300 million upfront commitment buys an early-stage pipeline option, not near-term sales. [#PR-2026-09-29-HRS1596] Company release.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-07 • Updated nightlySource: Internal modelMethodology